Exforge TPP — Settlement Summary

Last Modified on 09/22/2026 2:18 pm EDT

Exforge Antitrust Settlement (Third-Party Payors) — *In re Novartis and Par Antitrust Litigation*

Summary

This class action lawsuit alleges that Novartis Pharmaceuticals Corp. and Par Pharmaceutical, Inc. engaged in anticompetitive conduct that delayed the availability of generic Exforge® (amlodipine/valsartan tablets), causing End-Payor Class members to overpay for the drug. Novartis agreed to a $30,000,000 cash settlement to resolve claims brought by third-party payors and consumers who indirectly purchased or reimbursed for brand or generic Exforge. Claims against Par were separately dismissed after Par filed for bankruptcy in August 2022.

Announcements

- **Consumer payments issued:** Payments to the Consumer Class have already been distributed. Claimants with uncashed payments should expect to be contacted by the claims administrator regarding reissuance options.
- **TPP claims still processing:** Third-Party Payor (TPP) claims are still being processed as of the date of this article. Distribution to TPP claimants is anticipated in the coming months.
- **Filing deadline has passed:** The claim submission deadline was **August 18, 2023**. No new claims are being accepted at this time.

Settlement Amount

$30,000,000 cash settlement fund from Novartis. Per-claimant payment amounts for Third-Party Payors are not yet published; distributions are anticipated in the coming months. Consumer Class payments have already been issued.

Class Period

September 21, 2012 through June 30, 2018, covering indirect purchases of brand or AB-rated generic Exforge in the following jurisdictions: Arizona, California, the District of Columbia, Florida, Hawaii, Iowa, Maine, Michigan, Minnesota, Nebraska, Nevada, New Hampshire, New Mexico, New York, North Carolina, North Dakota, Oregon, South Dakota, Utah, Vermont, West Virginia, and Wisconsin.

Filing Deadline

August 18, 2023 (passed). Claim Forms were required to be postmarked (if mailed) or received online on or before August 18, 2023. The deadline to exclude or object was also August 18, 2023. No new claims are being accepted.

Who Qualifies

The End-Payor Class includes two groups of indirect purchasers of brand Exforge® and/or its AB-rated generic equivalents in the eligible states during the Class Period:

- **Third-Party Payors (TPPs):** All entities that purchased, paid for, and/or provided reimbursement for some or all of the purchase price of Exforge or its generic equivalents for consumption by their members, enrollees, or insureds.

- **Consumers:** All individuals who purchased or paid for some or all of the purchase price of Exforge or its generic equivalents, *except* those who:
    - Used a Novartis co-pay coupon or voucher while uninsured; or
    - Used a Novartis co-pay coupon or voucher that reduced their out-of-pocket payment to less than $15.00 while insured.

Who Is Excluded

- Defendants (Novartis and Par) and their counsel, officers, directors, management, employees, subsidiaries, or affiliates
- All federal and state governmental entities (except cities, towns, municipalities, or counties with self-funded prescription drug plans)
- All persons or entities who purchased Exforge for purposes of resale or directly from defendants or their affiliates
- Fully-insured health plans (plans that purchased insurance from another third-party payor covering 100% of the plan's reimbursement obligations to its members)
- Flat co-payors (consumers covered by plans applying the same fixed dollar co-payment to both branded and generic Exforge)
- Consumers who purchased only generic amlodipine valsartan (not branded Exforge) under a plan requiring a fixed dollar co-payment
- Pharmacy benefit managers
- Persons or entities purchasing only branded Exforge after September 30, 2014, and not amlodipine valsartan
- All counsel of record
- The court, court personnel, and any member of their immediate families

How to File

The claim filing deadline has passed (August 18, 2023). No new claims are being accepted. For clients who submitted claims prior to the deadline, the following applies:

- **TPP claimants:** Claims are still being processed. Distribution is anticipated in the coming months. Monitor communications from the settlement administrator for updates.
- **Consumer claimants with uncashed payments:** The administrator will contact affected claimants regarding options for reissuing payments.
- **Fix a claim:** The settlement website includes a "Fix Claim" option for claimants who need to correct a previously submitted claim.
- For questions, contact the settlement administrator via the settlement website's Contact Us page or refer to Class Counsel identified in the official Notice.

Defendants

- **Novartis Pharmaceuticals Corp. and Novartis AG ("Novartis"):** Manufacturer of brand-name Exforge®. Alleged to have engaged in anticompetitive conduct — specifically, entering into an unlawful agreement with Par — to delay generic competition and keep Exforge prices artificially high. Novartis is the settling defendant ($30,000,000).
- **Par Pharmaceutical, Inc. ("Par"):** Generic drug manufacturer alleged to have participated in the anticompetitive scheme. Par filed for bankruptcy on August 16, 2022 (Case No. 22-22546, S.D.N.Y.). The End-Payor Plaintiffs stipulated to dismiss their claims against Par with prejudice. Par is not a party to the settlement.

Case History

- **2018:** Lawsuit filed — *In re Novartis and Par Antitrust Litigation*, Case No. 1:18-cv-04361, in the U.S. District Court for the Southern District of New York.
- **August 16, 2022:** Par Pharmaceutical filed for bankruptcy (Case No. 22-22546, S.D.N.Y.).
- **2023 (prior to August 18):** Court granted preliminary approval of the $30,000,000 settlement with Novartis. End-Payor Plaintiffs stipulated to dismiss claims against Par with prejudice.
- **August 18, 2023:** Deadline for class members to submit claims, request exclusion, or file objections.
- **October 3, 2023:** Final Approval Fairness Hearing before U.S. District Court Judge Alvin K. Hellerstein, Courtroom 14D, Daniel Patrick Moynihan U.S. Courthouse, 500 Pearl Street, New York, NY 10007 (10:30 AM EDT).
- **Post-October 2023:** Consumer Class payments distributed. TPP claim distributions ongoing and anticipated in the coming months.

Source

Settlement website: **https://www.exforgeantitrustsettlement.com** (official site authorized by the U.S. District Court for the Southern District of New York)

Last Updated

2026-09-22

Reviewer Flags

- **First draft** — no previous version exists for comparison.
- **All information sourced from:** Exforge TPP Homepage (single monitored page).
- **Potential contradiction to flag:** The filing deadline passed on August 18, 2023, yet the settlement website remains active with a "Submit Claim" menu option as of the page capture. It is unclear whether the administrator is still accepting late claims or if the submit function is disabled. FRS staff should verify directly with the administrator before advising any client on late filing.
- **TPP distribution timing:** The homepage states distribution is "anticipated in the coming months" but provides no specific date. This language may be stale given the page was captured in 2026 — FRS staff should confirm current distribution status directly with the settlement administrator.
- **Per-claimant payment estimate:** No per-claimant or per-TPP payment estimate is published on the settlement website. The $30M gross settlement amount is the only figure available.
- **Fairness Hearing outcome:** The Fairness Hearing was scheduled for October 3, 2023, but the source page does not confirm whether Final Approval was granted. Given that consumer payments have been issued, Final Approval is strongly implied but not explicitly stated on the monitored page.